COGT Stock Forecast & Price Target

Cogent Biosciences is viewed favorably because bezuclastinib is advancing through three FDA reviews for KIT-driven diseases, creating multiple near-term catalysts in 2L GIST, NonAdvSM, and AdvSM. Its clinical profile appears compelling, with APEX showing a 54% ORR, 24% CR/CRh, and deep biomarker reductions, while 12-month PFS and OS rates of 79% and 87% support durability and differentiation versus competing KIT inhibitors. Financially, the company ended 2Q with $792.3M in cash, or $865.9M pro forma, providing runway into late 2028 and supporting launch readiness, which strengthens the case for meaningful commercial upside.

Cogent Biosciences is viewed negatively because its value case depends heavily on bezuclastinib and CGT9486 producing strong clinical data, yet the main near-term risk is poorer-than-expected results that could reduce market penetration, delay approval, or block approval altogether. The outlook is also pressured by meaningful regulatory, commercial, and competitive risks, including the emergence of better-than-expected competitor products and setbacks in later-stage trials or earlier-stage candidates. Despite a DCF framework assuming 95% probability of approval in advanced systemic mastocytosis, 95% in non-advanced systemic mastocytosis, and 90% in 2L GIST, the model still carries a 10% discount rate, a 29% effective tax rate, and long-term dilution risk that can erode returns.